Novel Inflammation-Based Prognostic Score for Predicting Survival in Patients with Metastatic Urothelial Carcinoma.
We developed a novel inflammation-based model (NPS), which consisted of a neutrophil to lymphocyte ratio (NLR) and platelet count (PC), for assessing the prognostic role in patients with metastatic urothelial carcinoma (UC).We performed a retrospective analysis of patients with metastatic UC who und...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2017-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5226814?pdf=render |
id |
doaj-9fe5a3ad672d46b0aa14798ca0cd7582 |
---|---|
record_format |
Article |
spelling |
doaj-9fe5a3ad672d46b0aa14798ca0cd75822020-11-25T02:43:08ZengPublic Library of Science (PLoS)PLoS ONE1932-62032017-01-01121e016965710.1371/journal.pone.0169657Novel Inflammation-Based Prognostic Score for Predicting Survival in Patients with Metastatic Urothelial Carcinoma.Yu-Li SuMeng-Che HsiehPo-Hui ChiangMing-Tse SungJui LanHao-Lun LuoChun-Chieh HuangCheng-Hua HuangYeh TangKun-Ming RauWe developed a novel inflammation-based model (NPS), which consisted of a neutrophil to lymphocyte ratio (NLR) and platelet count (PC), for assessing the prognostic role in patients with metastatic urothelial carcinoma (UC).We performed a retrospective analysis of patients with metastatic UC who underwent systemic chemotherapy between January 1997 and December 2014 in Kaohsiung Chang Gung Memorial Hospital. The defined cutoff values for the NLR and PC were 3.0 and 400 × 103/μL, respectively. Patients were scored 1 for either an elevated NLR or PC, and 0 otherwise. The NPS was calculated by summing the scores, ranging from 0 to 2. The primary endpoint was overall survival (OS) by using Kaplan-Meier analysis. Multivariate Cox regression analysis was used to identify the independent prognostic factors for OS.In total, 256 metastatic UC patients were enrolled. Univariate analysis revealed that patients with either a high NLR or PC had a significantly shorter survival rate compared with those with a low NLR (P = .001) or PC (P < .0001). The median OS in patients with NPS 0, 1, and 2 was 19.0, 12.8, and 9.3 months, respectively (P < .0001). Multivariate analysis revealed that NPS, along with the histologic variant, liver metastasis, age, and white cell count, was an independent factor facilitating OS prediction (hazard ratio 1.64, 95% confidence interval 1.20-2.24, P = .002).The NLR and PC are independent prognostic factors for OS in patients with metastatic UC. The NPS model has excellent discriminant ability for OS.http://europepmc.org/articles/PMC5226814?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Yu-Li Su Meng-Che Hsieh Po-Hui Chiang Ming-Tse Sung Jui Lan Hao-Lun Luo Chun-Chieh Huang Cheng-Hua Huang Yeh Tang Kun-Ming Rau |
spellingShingle |
Yu-Li Su Meng-Che Hsieh Po-Hui Chiang Ming-Tse Sung Jui Lan Hao-Lun Luo Chun-Chieh Huang Cheng-Hua Huang Yeh Tang Kun-Ming Rau Novel Inflammation-Based Prognostic Score for Predicting Survival in Patients with Metastatic Urothelial Carcinoma. PLoS ONE |
author_facet |
Yu-Li Su Meng-Che Hsieh Po-Hui Chiang Ming-Tse Sung Jui Lan Hao-Lun Luo Chun-Chieh Huang Cheng-Hua Huang Yeh Tang Kun-Ming Rau |
author_sort |
Yu-Li Su |
title |
Novel Inflammation-Based Prognostic Score for Predicting Survival in Patients with Metastatic Urothelial Carcinoma. |
title_short |
Novel Inflammation-Based Prognostic Score for Predicting Survival in Patients with Metastatic Urothelial Carcinoma. |
title_full |
Novel Inflammation-Based Prognostic Score for Predicting Survival in Patients with Metastatic Urothelial Carcinoma. |
title_fullStr |
Novel Inflammation-Based Prognostic Score for Predicting Survival in Patients with Metastatic Urothelial Carcinoma. |
title_full_unstemmed |
Novel Inflammation-Based Prognostic Score for Predicting Survival in Patients with Metastatic Urothelial Carcinoma. |
title_sort |
novel inflammation-based prognostic score for predicting survival in patients with metastatic urothelial carcinoma. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2017-01-01 |
description |
We developed a novel inflammation-based model (NPS), which consisted of a neutrophil to lymphocyte ratio (NLR) and platelet count (PC), for assessing the prognostic role in patients with metastatic urothelial carcinoma (UC).We performed a retrospective analysis of patients with metastatic UC who underwent systemic chemotherapy between January 1997 and December 2014 in Kaohsiung Chang Gung Memorial Hospital. The defined cutoff values for the NLR and PC were 3.0 and 400 × 103/μL, respectively. Patients were scored 1 for either an elevated NLR or PC, and 0 otherwise. The NPS was calculated by summing the scores, ranging from 0 to 2. The primary endpoint was overall survival (OS) by using Kaplan-Meier analysis. Multivariate Cox regression analysis was used to identify the independent prognostic factors for OS.In total, 256 metastatic UC patients were enrolled. Univariate analysis revealed that patients with either a high NLR or PC had a significantly shorter survival rate compared with those with a low NLR (P = .001) or PC (P < .0001). The median OS in patients with NPS 0, 1, and 2 was 19.0, 12.8, and 9.3 months, respectively (P < .0001). Multivariate analysis revealed that NPS, along with the histologic variant, liver metastasis, age, and white cell count, was an independent factor facilitating OS prediction (hazard ratio 1.64, 95% confidence interval 1.20-2.24, P = .002).The NLR and PC are independent prognostic factors for OS in patients with metastatic UC. The NPS model has excellent discriminant ability for OS. |
url |
http://europepmc.org/articles/PMC5226814?pdf=render |
work_keys_str_mv |
AT yulisu novelinflammationbasedprognosticscoreforpredictingsurvivalinpatientswithmetastaticurothelialcarcinoma AT mengchehsieh novelinflammationbasedprognosticscoreforpredictingsurvivalinpatientswithmetastaticurothelialcarcinoma AT pohuichiang novelinflammationbasedprognosticscoreforpredictingsurvivalinpatientswithmetastaticurothelialcarcinoma AT mingtsesung novelinflammationbasedprognosticscoreforpredictingsurvivalinpatientswithmetastaticurothelialcarcinoma AT juilan novelinflammationbasedprognosticscoreforpredictingsurvivalinpatientswithmetastaticurothelialcarcinoma AT haolunluo novelinflammationbasedprognosticscoreforpredictingsurvivalinpatientswithmetastaticurothelialcarcinoma AT chunchiehhuang novelinflammationbasedprognosticscoreforpredictingsurvivalinpatientswithmetastaticurothelialcarcinoma AT chenghuahuang novelinflammationbasedprognosticscoreforpredictingsurvivalinpatientswithmetastaticurothelialcarcinoma AT yehtang novelinflammationbasedprognosticscoreforpredictingsurvivalinpatientswithmetastaticurothelialcarcinoma AT kunmingrau novelinflammationbasedprognosticscoreforpredictingsurvivalinpatientswithmetastaticurothelialcarcinoma |
_version_ |
1724771327420661760 |